Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Balfour Beatty trading in line, lifts cash forecast

(Sharecast News) - Infrastructure group Balfour Beatty lifted its cash forecast on Thursday as it said trading since 1 January has been in line with expectations and it continues to expect an increase in profit from operations from its earnings-based businesses this year. In an update ahead of its annual meeting, the company said the positive momentum in its key markets has continued since the 2024 full-year results in March and that it remains committed to "a selective bidding approach in the continued pursuit of a high-quality and low-risk forward order book".

In the UK, the rail business has secured around £450m of new work, including civil engineering works under CP7, track renewal with the Central Rail Systems Alliance and fleet supply and operation for Network Rail.

Meanwhile, Balfour's US Buildings business has been awarded a $385m contract to construct the Grand Hyatt Miami Beach. The 17 storey hotel includes convention spaces and retail areas and is scheduled for completion in late 2027.

In addition, the group's US Civils business has been awarded a $889m contract by the Texas Department of Transportation to reconstruct a 3.7-kilometre section of Interstate 30 on the east side of Dallas County.

Balfour said that over the first three months of this year, the average monthly closing net cash balance was £1.06bn, versus a FY2024 average of £766m and closing of £943m.

Given the strong cash performance in the year to date, it now expects 2025 average net cash in the range of £900m to £1bn.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.